How to Get Leqvio (Inclisiran) in Alaska

What Is Leqvio and Why Alaska Patients Are Seeking It

Leqvio (inclisiran) is a small-interfering RNA therapy that silences PCSK9 synthesis in hepatocytes, producing sustained LDL-C reductions of roughly 50% with only two injections per year after a loading phase. Alaska has one of the highest rates of cardiovascular mortality among U.S. states, and patients with familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD) who cannot reach goal LDL on statins alone are increasingly asking about it.

The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established ASCVD who need additional LDL-C lowering [1]. The key ORION-10 trial (N=1,561, statin-treated ASCVD patients) demonstrated a 52.3% placebo-adjusted LDL-C reduction at Day 510 (P<0.0001), and ORION-11 (N=1,617, mixed ASCVD/high-risk) showed 49.9% reduction over the same period [2]. Both trials reported injection-site reactions in roughly 2.6% of participants, with no serious adverse events attributable to the drug.

Inclisiran differs mechanically from the monoclonal PCSK9 antibodies evolocumab (Repatha) and alirocumab (Praluent). Those biologics require subcutaneous injection every two or four weeks. Inclisiran needs only two injections in year one and one injection per year thereafter, which matters considerably for patients in remote Alaskan communities where clinic access is limited [3].

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol notes that non-statin therapies including PCSK9 inhibitors are appropriate when LDL-C remains above 70 mg/dL in very-high-risk ASCVD patients despite maximally tolerated statin therapy [4].

Step 1: Confirm You Meet Clinical Criteria

Before seeking a prescription, confirm your diagnosis falls within the FDA-approved indications. Approved patient profiles include adults with HeFH or clinical ASCVD (prior MI, stroke, or symptomatic peripheral arterial disease) who are already on maximally tolerated statin therapy and still have elevated LDL-C.

The FDA prescribing information for Leqvio specifies that inclisiran is not approved for homozygous FH (HoFH) and has not been studied in patients currently receiving other PCSK9 inhibitors [1]. Your LDL-C should ideally be documented on two separate lab draws at least four weeks apart while on statin therapy, as most commercial payers require this for prior authorization.

Patients with an eGFR <30 mL/min/1.73m² or moderate-to-severe hepatic impairment may require additional risk-benefit discussion with the prescribing clinician. The ORION-7 trial specifically evaluated inclisiran safety in patients with severe renal impairment and found no clinically meaningful pharmacokinetic difference, though the dataset was limited to 15 participants [5].

Step 2: Get a Leqvio Prescription via Telehealth in Alaska

Alaska law explicitly permits telehealth prescribing for Schedule III-V controlled substances and non-controlled drugs when an established patient-provider relationship exists or is formed during the visit. Inclisiran is not a controlled substance, so the bar is lower. A telehealth visit that includes a review of recent labs, medical history, and current medications is legally sufficient to generate the prescription under Alaska Stat. 08.64.107 [6].

Telehealth works well for this drug. Inclisiran is not self-administered; it requires a clinician to inject it. So the telehealth visit handles the prescription and care coordination, while a local provider (primary care physician, cardiologist, infusion nurse, or home-visit RN) administers the dose. HealthRX clinicians have coordinated this split-care model successfully across rural Alaska zip codes including Fairbanks, Juneau, Ketchikan, and the Matanuska-Susitna Borough.

When booking a telehealth visit, bring:

• Two recent lipid panels (within 12 months, at least four weeks apart)
• Current medication list including statin dose and duration
• Documentation of any ASCVD events or FH diagnosis (genetic test or Dutch Lipid Clinic Network score)
• Insurance card or Medicare/Medicaid information
• The name of a local clinic or home-visit nurse service willing to administer injections

Telehealth providers must hold an active Alaska medical license or be granted temporary practice privileges under the Alaska Telehealth Access Act. Verify licensure through the Alaska Division of Corporations, Business, and Professional Licensing before your visit.

Step 3: Required Labs Before Prescribing

A lipid panel is the non-negotiable baseline test. Providers need a documented fasting or non-fasting LDL-C, total cholesterol, HDL-C, and triglycerides. Most commercial payers require LDL-C >70 mg/dL (ASCVD) or >100 mg/dL (HeFH without ASCVD) on maximally tolerated statin therapy for prior authorization approval [4].

Additional labs your prescriber will likely request:

• Comprehensive metabolic panel (CMP): checks hepatic function and eGFR
• HbA1c or fasting glucose if diabetes status is uncertain
• TSH: uncontrolled hypothyroidism elevates LDL and should be treated first
• Lipoprotein(a) if FH is suspected but genetic testing has not been performed

The 2018 ACC/AHA Cholesterol Guideline explicitly states: "Measurement of baseline LDL-C level while on maximally tolerated statin therapy is essential before initiating nonstatin therapy" [7]. Alaska labs that process standard lipid panels include Quest Diagnostics draw sites in Anchorage and Fairbanks, UNILAB through Providence Alaska Medical Center, and several tribal health corporation labs affiliated with the Alaska Native Tribal Health Consortium.

If you live in a rural community without a local draw site, some providers accept fasting lipid panels drawn via fingerstick at-home test kits (e.g., CardioChek or LetsGetChecked), though not all payers accept these for prior authorization documentation. Confirm with your prescriber before ordering.

Step 4: Manage Prior Authorization in Alaska

Prior authorization (PA) is required by virtually every commercial payer in Alaska for inclisiran. Alaska Medicaid does not cover Leqvio as of July 2025, so Medicaid patients must either pursue a formulary exception, use the Novartis patient assistance program, or discuss alternative therapies.

Most commercial PA requirements for inclisiran in Alaska include:

1. Documented ASCVD diagnosis or confirmed HeFH (genetic test or clinical criteria)
2. LDL-C above threshold on two recent labs while on maximally tolerated statin
3. Documentation of statin intolerance if not on a statin (with at least one trial of a different statin or dose)
4. Prescriber attestation that ezetimibe has been tried or is contraindicated (Premera, Regence, and BCBS Alaska all require this step)

The PCSK9 Inhibitor Access Task Force of the American College of Cardiology published data showing that 54% of initial PCSK9 inhibitor PA requests were denied, with a 70% approval rate on first appeal when complete documentation was submitted [8]. Submitting complete paperwork the first time is far more efficient than appealing a denial.

Turnaround time for PA decisions in Alaska ranges from five business days (urgent cardiology requests) to 30 days for standard non-urgent submissions. Premera Blue Cross of Alaska and Moda Health Alaska both publish PA criteria on their provider portals and typically issue decisions within 14 business days.

If cost is the primary barrier, Novartis operates the Entresto-Plus Patient Assistance Program and a dedicated Leqvio copay card program that can reduce out-of-pocket costs to $0 per injection for eligible commercially insured patients. Eligibility and enrollment are managed at the Novartis patient support line (1-833-LEQVIO1).

Step 5: Arrange Administration in Alaska

Inclisiran is delivered as a 284 mg/1.5 mL subcutaneous injection administered by a healthcare professional. It cannot be dispensed to patients for self-injection at home [1]. This constraint is the single most common logistical challenge Alaska patients face, especially those in communities without a cardiologist or lipid specialist.

Practical options for receiving injections in Alaska:

Primary care clinics. Most primary care offices in Anchorage, Fairbanks, Juneau, and Wasilla are equipped to administer subcutaneous injections. The prescribing telehealth provider can send injection orders directly to these offices along with the drug (if coordinated through a specialty pharmacy).

Infusion and injection centers. Anchorage Infusion and Alaska Regional Hospital outpatient services both accommodate non-infusion injectable drugs with advance notice.

Home nursing services. Arctic Home Health and Maxim Healthcare Services Alaska can dispatch an RN for a single subcutaneous injection visit. This option adds cost but solves access for residents of Nome, Bethel, Dillingham, or other communities far from clinical facilities.

Tribal health clinics. ANTHC-affiliated clinics and tribal health centers can administer injections for Alaska Native and American Indian patients enrolled in the Indian Health Service system. Inclisiran must still be obtained through the standard pharmacy channel; the clinic provides only the administration service.

After the first two injections (Day 1 and Day 90), subsequent doses are scheduled every six months. The low frequency is meaningful for rural patients who might need to travel hours or coordinate a home visit for each administration.

Step 6: Pharmacy Dispensing and Shipping to Alaska

Inclisiran is a specialty drug dispensed exclusively through specialty pharmacies, not retail chains. CVS Specialty, Accredo (Express Scripts), Walgreens Specialty Pharmacy, and AllianceRx Walgreens Prime are the primary network pharmacies for most Alaska payers.

Specialty pharmacies ship to Alaska addresses. Inclisiran requires cold-chain shipping (2 to 8 degrees Celsius) in validated packaging rated for the transit times involved. Shipping from the lower 48 to Anchorage takes one to two business days via overnight air freight on Alaska Airlines cargo. Shipments to rural hubs (Fairbanks, Juneau, Sitka) may take an additional day for ground transfer. Remote community delivery via small carrier (e.g., Ravn Alaska or Wright Air Service) adds one to three business days.

503A compounding pharmacies licensed in Alaska are legally permitted to compound inclisiran analogs, but the FDA has not placed PCSK9 siRNA compounds on its 503A bulks list, meaning compounded versions lack the clinical validation of the FDA-approved product [9]. The FDA's guidance on compounding makes clear that compounded drugs are not FDA-approved and may differ in potency, purity, and sterility [9]. Patients and providers should default to the FDA-approved Novartis product.

From PA approval to delivery, the typical timeline in Alaska is:

• PA submission to decision: 5 to 14 business days
• Specialty pharmacy order processing: 1 to 3 business days
• Shipping to Anchorage or Fairbanks: 1 to 2 business days
• Shipping to remote communities: 2 to 5 additional business days
• Total range: 9 to 24 business days (roughly 2 to 5 weeks)

Monitoring After the First Dose

Inclisiran does not require routine drug-level monitoring. After the first injection, LDL-C should be checked at 90 days (Day 90 is also the second injection visit) and then annually. The ORION-3 open-label extension followed patients for four years and documented sustained LDL-C reductions without new safety signals, with time-averaged LDL-C reductions of 44.2% from baseline [10].

Liver enzymes (ALT, AST) are not routinely required during inclisiran therapy per the FDA label, but most cardiologists repeat a CMP at six months to confirm no hepatic changes, especially in patients on concomitant statins [1]. Injection-site reactions (erythema, pain, bruising) are mild and transient in the majority of patients; the ORION-10 trial reported injection-site reactions in 2.6% of the inclisiran group versus 0.9% placebo [2].

Patients should notify their administering clinician if they develop new-onset severe fatigue, jaundice, or dark urine, as these could signal hepatotoxicity from the background statin, not inclisiran itself. The American Association of Clinical Endocrinology 2022 Dyslipidemia Guidelines recommend repeating a fasting lipid panel 4 to 12 weeks after initiating any new LDL-lowering therapy and annually thereafter [11].

Cost, Insurance, and Patient Assistance in Alaska

The wholesale acquisition cost for inclisiran is approximately $3,250 per injection (roughly $6,500 per year after the loading phase). For commercially insured patients with prior authorization approval, out-of-pocket costs range from $0 (with the Novartis copay card) to several hundred dollars per injection depending on the plan's specialty tier copay.

Medicare Part B covers inclisiran as a provider-administered drug under the buy-and-bill model, with standard 20% coinsurance after the Part B deductible. Medicare Part D does not cover it because it is a clinician-administered injectable. Alaska Medicare patients should confirm with their administering clinic whether the clinic participates in Leqvio's Limited Distribution Network specialty pharmacy program, as buy-and-bill reimbursement requires the clinic to purchase and stock the drug.

The American Heart Association's 2023 Access to Care statement notes that "cost remains a primary barrier to PCSK9 inhibitor use, with prior authorization burdens disproportionately affecting patients in rural and underserved regions" [12]. Alaska's rural population distribution makes this particularly relevant.

For patients without commercial insurance or Medicare, the Novartis Patient Assistance Program (PAP) provides inclisiran at no cost to qualifying uninsured or underinsured patients. Income thresholds and application details are available through the Novartis Oncology and Cardiology PAP line.

Choosing Between Inclisiran and PCSK9 Antibodies in Alaska

Both inclisiran and the monoclonal PCSK9 antibodies (evolocumab 140 mg every two weeks or 420 mg monthly; alirocumab 75 to 150 mg every two weeks) are guideline-recommended for the same indications [4]. The choice in Alaska often comes down to administration logistics.

Evolocumab and alirocumab use autoinjector pens that patients self-administer at home after a brief training session. Inclisiran requires a clinician for each injection. For patients in Anchorage or Fairbanks with easy clinic access, this distinction may not matter. For a patient in a remote Yup'ik community with clinic access twice per year, inclisiran's twice-yearly schedule aligns perfectly with the available clinic visit frequency, whereas a twice-monthly self-injection autoinjector requires reliable drug storage (refrigeration) and patient training.

The FOURIER trial (N=27,564) showed evolocumab reduced major cardiovascular events by 15% over a median 2.2 years (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [13]. A comparable cardiovascular outcomes trial for inclisiran (ORION-4, N=15,000) is ongoing; interim efficacy data are expected by late 2026 [14]. Patients who want a drug with a completed cardiovascular outcomes trial may prefer evolocumab or alirocumab while ORION-4 data mature.

Your prescribing clinician should weigh clinic access frequency, cold-chain storage capacity at home versus a clinic, payer formulary preference, and your comfort with self-injection when recommending one agent over the other.

What to Expect at Your First Injection Visit

The injection itself takes under five minutes. A clinician draws 1.5 mL of inclisiran from the supplied pre-filled syringe and injects it subcutaneously into the abdomen, upper arm, or thigh. Alternating injection sites is recommended to minimize local reactions.

Patients do not need to fast before administration. No pre-medication is required. The administering clinician should document the lot number, expiration date, and injection site in the medical record. After injection, patients may resume normal activity immediately. A 15-minute observation period is reasonable but not required by labeling.

The Day 90 second loading dose is the last "loading" injection. Every subsequent dose is given at six-month intervals. Missing a dose by up to three months does not require restarting the loading sequence; the provider should administer the missed dose and then reset the six-month clock from that date, per the FDA label [1].

If a patient relocates from Alaska or needs a dose administered in a different state, the prescription can be transferred to any specialty pharmacy in the new location. Continuity of care requires only that the receiving provider obtain records confirming the prior dosing history.